Inspiring breakthroughs to advance industry innovations
Combining world-class talent with cutting-edge technology, Catalent was created in April 2007 when The Blackstone Group, a premier global investment and advisory firm, acquired the Pharmaceutical Technologies and Services segment of Cardinal Health. The acquisition created a global network of experts and facilities dedicated to the advanced development, delivery, and supply of drug products, with over 75 years of pharmaceutical and consumer health experience and nearly 20 years serving the biotechnology industry. Today, a market leader in nearly every area of drug development, Catalent has broad and deep relationships throughout the globe, manufacturing nearly half of all new drug approvals and producing 30 doses every second
Our full range of offerings and services follow the complete lifecyle of drug production – from development to delivery to supply and beyond.
2014 and on
In July, Catalent announces the next step in the growth journey as the Global Leader and the #1 Pharmaceutical Industry Partner in Advanced Drug Delivery Technologies and Drug Development Solutions by becoming a publicly traded company on the NYSE.
Catalent continues to target emerging markets and entered into two joint ventures in China, which provided majority control of both a softgel manufacturer and a newly established clinical supply business.
In October, Catalent acquired a softgel manufacturing business in Brazil.
Catalent expands the existing clinical supply offerings by acquiring the Aptuit CTS business and completing the integration.
Catalent purchased the remaining 49% minority share ownership the RP Scherer softgel subsidiary located in Eberbach, Germany.
Catalent drives growth by updating strategy and targeting emerging markets, in-organic licensing, and M&A opportunities.
New CEO and leadership team form new business unit and invest in innovation.
Divested from Cardinal, Catalent emerges as a private, independent company under The Blackstone Group.
Cardinal acquires more businesses, facilities, and technologies in oral manufacturing and packaging and refocuses on downstream providers.
Cardinal enters fee-for-service analytical chemistry market by acquiring Magellan Labs, leader in analytical science services for U.S. pharmaceuticals.
Cardinal acquires SP Pharmaceuticals, LLC (sterile fill/finish manufacturing and lyophilization for injectables) and International Processing Corp. (oral solid coating and dose manufacturing).
Cardinal acquires Automatic Liquid Packaging, Inc., leader in blow-fill-seal technology for respiratory treatments, ophthalmics, and other areas.
Cardinal acquires R.P. Scherer Corp., leader in advanced oral drug delivery technologies that commercialized softgel manufacturing in the 1930s.
Cardinal acquires PCI Services, Inc., leader in outsourced packaging for Rx and OTC pharmaceuticals, veterinary, and other products.
Enhancing products, changing lives
As experts in improving drug performance, we are well known for introducing numerous innovations to market:
Commercialization of softgel manufacturing
in the 1930s and continued innovation of oral dose formulation over seven decades
Launch of the “fast-dissolve” dose
form category with the commercialization of our Zydis® technology in the 1980s
Introduction of Vegicaps® capsules
a vegetable-based softgel shell system - in 2001
Three decades of packaging innovation
in patient and physician sample kits, child resistant/senior-friendly designs, unit dose technology (DelPouch® packaging), and patient adherence-enhancing packaging
breakthrough mammalian cell line engineering that is faster, more reliable, and more flexible than traditional methods
a state-of-the-art solid-form screening service that ensures maximum API optimization